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Abstract: At present, more than 100 disease mutations in mitochondrial DNA polymerase γ 
(POLG) have been indentified that are causally related to an array of neuropsychiatric diseases 
affecting multiple systems. Both autosomal recessive and autosomal dominant forms can be 
delineated, the latter being associated with Parkinsonism and depressive or psychotic syndromes. 
In this report, a middle-aged female patient with recurrent major depression with melancholic 
features, slowly progressive gait instability, and dilated cardiomyopathy is described. Detailed 
diagnostic evaluation was performed to elucidate the supposed relationship between ataxia, 
cardiomyopathy, and major depression with melancholia. After extensive genetic and metabolic 
investigation, a nucleotide substitution c.2207 A→G in the POLG gene resulting in amino acid 
change Asn 736Ser in exon 13 was demonstrated. This mutation was considered to be compat-
ible with a mitochondrial disorder and implicated in the pathophysiology of the neuropsychi-
atric syndrome. It is concluded that this novel POLG mutation forms the most parsimonious 
etiological explanation for the here-described combination of ataxia, major depression, and 
cardiomyopathy. Therefore, in patients with a complex neuropsychiatric presentation, extensive 
diagnostic analysis is warranted, including the search for mitochondriopathies, in order to avoid 
unnecessary delay of adequate treatment.
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Introduction
Cerebellar ataxias, of which the spinocerebellar ataxias (SCAs) are the most prevalent, 
represent a heterogeneous group of neurodegenerative disorders that, according to their 
genetic etiology, can be differentiated among autosomal dominant, autosomal recessive, 
X-linked, and maternally inherited syndromes.1,2 Over the last decade, novel mitochon-
drial genetic diseases have been identified in which mutations in DNA polymerase γ 
(POLG [MIM 174763]) gene are involved. POLG1 is the only DNA polymerase in 
human mitochondria and is essential for mitochondrial (mt)DNA replication and repair. 
It has to be stressed that functional genetic variants of POLG are present in about 0.5 
percent of the normal population. Defects in mtDNA replication lead to mitochondrial 
dysfunction and disease. Originally, primary mtDNA mutations were thought to be the 
major cause of human mitochondriopathies.3 Nowadays, however, a great number of 
novel diseases have been described in which POLG mutations are causative through a 
secondary effect on mtDNA. These syndromes are thought to have a common European 
ancestry and may manifest from early infancy to late middle age.4,5
To date, POLG mutations have been found to be causal in a great number of 
mitochondrial diseases with a very heterogeneous clinical manifestation and affecting 
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multiple systems.6 In 2001, Van Goethem and coworkers 
identified a mutation in POLG in a Belgian pedigree with 
progressive external ophthalmoplegia.7 Thereafter, muta-
tions in POLG were found in a great variety of diseases 
like Alpers syndrome, SCA negative cerebellar ataxia, and 
Charcot-Marie-Tooth disease.8–10
POLG mutations cause an overlapping clinical spectrum 
of diseases with both dominant and recessive modes of 
inheritance. Autosomal recessive forms often present with 
external ophthalmoplegia, peripheral neuropathy, ataxia, and 
epilepsy.5,11 Autosomal dominant forms are mostly character-
ized by symptoms within the ataxia-neuropathy range and by 
progressive external ophthalmoplegia. In addition, these auto-
somal dominant syndromes are reported to be associated with 
an array of neuropsychiatric symptoms from the  Parkinson 
spectrum and from the psychotic and depressive domains of 
which major depression has the highest incidence.12–14
In this report, a middle-aged female patient is described 
with a long history of recurrent depression and slowly pro-
gressive gait instability, as well as dilated cardiomyopathy for 
the 5-year period prior to admission. A descriptive diagnosis 
of progressive cerebellar ataxia with bilateral pyramidal 
syndrome and cardiomyopathy was made. Later, extensive 
genetic work-up demonstrated a POLG mutation which was 
thought to be of pathogenic significance.
Clinical observations and results
The patient is a 52-year-old single female born from non-
consanguineous parents. She has three healthy sisters. Her 
only brother died in his early fifties, allegedly from gastric 
hemorrhage. Her mother and father died aged 55 and 80 from 
acute cardiac arrest, most probably due to cardiomyopathy, 
and cerebral hemorrhagia respectively. There is no family 
history of mental disorders or hereditary diseases. At the 
age of 33 she gave birth to a healthy son who is mildly men-
tally retarded. The patient showed a normal developmental 
trajectory, completed primary school followed by domestic 
training, and was subsequently employed in nondemanding 
jobs. Aged 17, she was involved in a serious car accident 
resulting in cerebral concussion and various fractures of the 
right foot and knee for which she underwent several orthope-
dic surgical corrections. Since that time, the patient showed 
an unstable gait and balance, which with physical therapy 
gradually disappeared. For a period of 20 years, she was able 
to perform her elementary activities at a laundry, not hindered 
by motor impairments. At the age of 37 years,  however, she 
was referred to a rehabilitation physician because she’d had 
slowly progressive gait instability for a period of 2 years. 
Physical examination disclosed a mild ataxia that was 
interpreted as a result of the cerebral concussion. In addi-
tion, emotional and affective instability were noticed. No 
neuroradiological investigation was performed.
Over subsequent years, the patient showed recurrent 
depressive symptoms for which she was treated by her 
general practitioner with several antidepressants. Aged 44, 
she underwent surgery for bilateral subcapsular posterior 
cataract. At the same age, she was admitted to a psychiatric 
hospital because of domestic neglect, inactivity, paranoid ide-
ation, and symptoms of major depression with melancholic 
features. Neurological examination demonstrated bilateral 
ataxia and a slightly dysarthric speech. CT (computed 
tomography)-scanning of the brain revealed a moderate cer-
ebellar atrophy. The neurological symptoms were considered 
to be of posttraumatic origin. Treatment with clomipramine 
resulted in complete remission of depressive symptoms, and 
the patient was followed up at the outpatient department of 
psychiatry. At the age of 47, she developed complaints of 
fatigue and shortness of breath for which she was referred to 
a cardiologist. A diagnosis of dilated cardiomyopathy with 
a cardiac output of less than 30% was made, and treatment 
with the beta blocker bisoprolol was started. Over the sub-
sequent 6 years, several depressive episodes with psychotic 
phenomena and suicidal events occurred that were treated 
with various psychotropic agents. Because of serious impair-
ment of general functioning and persistent depressive and 
psychotic symptoms, the patient was referred to the special-
ized department of neuropsychiatry for extensive diagnostic 
assessment.
At admission, extreme loss of energy and marked hypoki-
nesia were prominent, and as a consequence, the patient was 
partially wheelchair bound. Since these phenomena were 
caused by her cardiomyopathy and use of antipsychotics 
respectively, treatment with bisoprolol was first optimalized 
and psychotropics were gradually tapered off. Thereafter, 
neuropsychiatric examination revealed a slight paranoid 
ideation and suicidal thoughts. There was significant loss of 
initiative, flattening of affect, depressed/dysphoric mood, 
and delusional ideas of nihilism, as well as anosognosia. 
Neuropsychological functioning was characterized by mark-
edly lowered information processing and a relatively intact 
working memory. Her total IQ was 69 (WAIS-III15), indica-
tive of below average intellectual functioning. The patient 
was friendly and cooperative but refused an extensive testing 
program. ECG-recording showed an incomplete left ven-
tricular bundle branch block with inverted T-waves. Routine 
hematological and biochemical laboratory tests disclosed a 
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mild dyslipidemia only (cholesterol 6.7 mmol/L, with other 
lipid parameters normal).
Treatment with citalopram in a maximal dose of 20 mg 
daily resulted in a gradual reduction of depressive symptoms, 
even though inactivity and loss of energy persisted and 
cerebellar dysfunctions became more prominent. An MRI 
(magnetic resonance imaging) scan of the brain demonstrated 
marked cerebellar atrophy without any supratentorial lesions 
(Figure 1). Karyotyping revealed no abnormalities.
Given the combination of ataxia and cardiomyopathy, the 
possibility of a hereditary spinocerebellar ataxia was con-
sidered, and hence an extensive neurological and etiological 
diagnostic procedure was started.
At neurological examination, the patient presented with 
slow speed and lack of initiative. Funduscopy revealed no 
abnormalities. There were saccadic intrusions of ocular 
smooth pursuit. Minimal bilateral thenar atrophia was 
noticed. No pareses were present. Speech was dysarthric and 
gait slightly ataxic but with normal base. All cerebellar tests 
were impaired. Sensibility was undisturbed in all modalities. 
Tendon reflexes of the arms and legs were hyperactive with 
bilateral positive Hoffmann–Trömner and Babinski signs. 
Snout reflex was present. An initial descriptive diagnosis 
of progressive cerebellar ataxia with bilateral pyramidal 
 syndrome and cardiomyopathy, present for over a decade, was 
given. With mutation analysis, all known autosomal reces-
sive cerebellar ataxias were excluded. Metabolic diseases 
like cerebrotendinous xanthomatosis and sphingolipidoses, 
especially Niemann–Pick disease type C, could not be dem-
onstrated. The spectrum of amino acids in plasma as well as 
the levels of lactate and pyruvate were all normal. Mutation 
analysis of the POLG gene demonstrated a nucleotide sub-
stitution c.2207 A→G resulting in amino acid change Asn 
736Ser, which with sequence analysis appeared to be located 
in exon 13. This mutation was considered to be compatible 
with a mitochondrial disorder and assumed to be implicated 
in the pathophysiology of the neurological syndrome and 
the cardiomyopathy.
Thus, a provisional diagnosis of a mitochondrial POLG 
disease was made, probably an autosomal dominant heterozy-
gotic form. Unfortunately, its clinical significance could not 
further be substantiated, since family members, in particular 
the son, were not available for additional testing. Although 
the depressive symptoms were no longer prominent, chronic 
hospitalization was necessary because of a slowly progres-
sive increase of both cardiac dysfunction and neurological 
symptoms.
Discussion
The case described here is a typical example of a patient 
in whom an apparently common psychiatric disease, major 
depression, was initially diagnosed. Detailed recording of 
her medical life chart and family history, however, was 
indicative of the presence of a complex neurodegenerative 
disorder characterized by slowly progressive cerebellar ataxia 
and cardiomyopathy. Such a combination of symptoms goes 
along with a vast amount of differential diagnostic options, 
including hereditary ataxias and metabolic disorders (eg, 
lysosomal storage diseases, disturbances in amino acid 
metabolism, and cerebral cholesterosis). By means of exten-
sive laboratory and genetic testing, all diagnostic hypotheses, 
other than a POLG mutation disease, could be falsified. In 
this patient, therefore, a tentative diagnosis of a POLG mis-
sense mutation was made.
Since there is an abundance of nucleotide substitutions 
that have been described in patients, Horvath and colleagues 
point at the diagnostic challenge that has to be mastered and 
provide a set of heuristic decision rules that delimit the clini-
cal significance of a POLG mutation.16 The first principle 
states that the amino acid change is located in a functional 
relevant site of POLG. A second criterion is that that the 
Figure 1 Axial, T2-weighted magnetic resonance image of the patient, showing 
atrophy of the cerebellum and the cerebellar vermis.
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mutation under study should be close to other established 
pathogenic POLG mutations. Given these principles and, in 
this case, the constellation of symptoms and the nucleotide 
change in the mutation c.2207 A→G, this novel mutation 
was considered to be pathogenically involved despite there 
being no information available on this mutation in normal 
populations.
It is well known that disorders within the mood and 
anxiety domain may be the initial sign of mitochondrial 
disorders. In fact, the prevalence in mitochondriopathies of 
a lifetime diagnosis of major depressive disorder is 54%.17 
From several studies, it emerges that impairment of metabo-
lism, especially at the mitochondrial level, may be involved 
in the pathophysiology of psychiatric diseases, including 
depressive disorders.18 Also POLG mutations have been 
reported to be associated with major depression.13 Therefore, 
major depression with melancholia as present in the current 
patient may be considered as part of the POLG-associated 
neuropsychiatric syndrome.
In conclusion, the presented case demonstrates a previ-
ously unreported POLG mutation accompanied by ataxia, 
cardiomyopathy, and major depression. Given the very 
heterogeneous phenotypical presentation of this multisystem 
disease, mutations involving the POLG gene should be con-
sidered in patients with major depressive disorder in whom 
a combination of unexplained neurological (eg, ataxia) and 
nonneurological (eg, cardiac dysfunction) is present.
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